GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tourmaline Bio Inc (NAS:TRML) » Definitions » Total Liabilities

Tourmaline Bio (Tourmaline Bio) Total Liabilities : $5.03 Mil (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Tourmaline Bio Total Liabilities?

Tourmaline Bio's Total Liabilities for the quarter that ended in Mar. 2024 was $5.03 Mil.

Tourmaline Bio's quarterly Total Liabilities declined from Sep. 2023 ($8.19 Mil) to Dec. 2023 ($5.25 Mil) and declined from Dec. 2023 ($5.25 Mil) to Mar. 2024 ($5.03 Mil).

Tourmaline Bio's annual Total Liabilities increased from Dec. 2021 ($0.38 Mil) to Dec. 2022 ($28.83 Mil) but then declined from Dec. 2022 ($28.83 Mil) to Dec. 2023 ($5.25 Mil).

Tourmaline Bio Total Liabilities Historical Data

The historical data trend for Tourmaline Bio's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tourmaline Bio Total Liabilities Chart

Tourmaline Bio Annual Data
Trend Dec21 Dec22 Dec23
Total Liabilities
0.38 28.83 5.25

Tourmaline Bio Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Liabilities Get a 7-Day Free Trial Premium Member Only - 134.13 8.19 5.25 5.03

Tourmaline Bio Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Tourmaline Bio's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=5.002+(0.194+0.057
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=5.25

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=210.295-205.042
=5.25

Tourmaline Bio's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=4.827+(0.153+0.05
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=5.03

Total Liabilities=Total Assets (Q: Mar. 2024 )-Total Equity (Q: Mar. 2024 )
=359.169-354.139
=5.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tourmaline Bio Total Liabilities Related Terms

Thank you for viewing the detailed overview of Tourmaline Bio's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Tourmaline Bio (Tourmaline Bio) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tourmaline Bio Inc (NAS:TRML) » Definitions » Total Liabilities
Comparable Companies
CYTK NUVL KRYS CRSP INSM FOLD BPMC IMGN AXSM ACAD OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
27 West 24th Street, Suite 702, New York, NY, USA, 10010
Website
https://www.tourmalinebio.com
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.